GILEAD SCIENCES SL
- Country
- 🇺🇸United States
- Ownership
- -
- Established
- 1994-01-01
- Employees
- -
- Market Cap
- $95.8B
Ledipasvir/Sofosbuvir Fixed-Dose Combination for 12 or 24 Weeks in Genotype 1 or 4 HCV Infected Adults With Sickle Cell Disease
- Conditions
- Hepatitis C Virus Infection
- Interventions
- Drug: LDV/SOF
- First Posted Date
- 2014-11-26
- Last Posted Date
- 2018-11-19
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 10
- Registration Number
- NCT02301936
Effect of Eleclazine on Shortening of the QT Interval, Safety, and Tolerability in Adults With Long QT Syndrome Type 3
- Conditions
- Long QT Syndrome Type 3
- Interventions
- First Posted Date
- 2014-11-25
- Last Posted Date
- 2018-01-12
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 41
- Registration Number
- NCT02300558
- Locations
- 🇨🇦
Nova Scotia Health Authority, Halifax, Nova Scotia, Canada
🇫🇷Groupe Hospitalier Bichat Claude Bernard, Paris, France
🇫🇷CHU Réunion Sud, Saint-Pierre, France
Efficacy And Safety Of Sofosbuvir/Velpatasvir Fixed Dose Combination With Ribavirin in Chronic HCV Infected Adults Who Participated in a Prior Gilead Sponsored HCV Treatment Study
- First Posted Date
- 2014-11-24
- Last Posted Date
- 2018-11-16
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 69
- Registration Number
- NCT02300103
Study to Evaluate the Pharmacokinetics of Tenofovir Alafenamide (TAF) in Adults With Normal Hepatic Function and Adults With Severe Hepatic Impairment
- First Posted Date
- 2014-11-20
- Last Posted Date
- 2020-12-09
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 20
- Registration Number
- NCT02296853
A Registry for Participants With Cirrhosis Who Achieve a Sustained Virologic Response Following Treatment With a Sofosbuvir-Based Regimen Without Interferon for Chronic Hepatitis C Infection
- Conditions
- Hepatitis C Virus Infection
- Interventions
- Other: Ineligible parent treatmentDrug: Other SOF-Based RegimenDrug: LDV/SOF
- First Posted Date
- 2014-11-17
- Last Posted Date
- 2023-10-04
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 1609
- Registration Number
- NCT02292706
- Locations
- 🇺🇸
Gastrointestinal Specialists of Georgia, PC, Marietta, Georgia, United States
🇺🇸North Shore Health Inc., Manhasset, New York, United States
🇺🇸Asheville Gastroenterology Associates, PA, Asheville, North Carolina, United States
Effect of Eleclazine (GS-6615) on Exercise Capacity in Subjects With Symptomatic Hypertrophic Cardiomyopathy
- First Posted Date
- 2014-11-14
- Last Posted Date
- 2018-09-24
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 172
- Registration Number
- NCT02291237
- Locations
- 🇮🇹
Azienda Ospedaliera San Camillo Forlanini, Rome, Italy
🇳🇱Academisch Medisch Centrum Amsterdam, Amsterdam, Noord-Holland, Netherlands
🇮🇹Azienda Ospedaliera Papa Giovanni XXIII, Bergamo, Italy
Study To Evaluate Emtricitabine/Tenofovir Alafenamide (F/TAF) in Human Immunodeficiency Virus 1 (HIV-1) Infected Children and Adolescents Virologically Suppressed on a 2- Nucleoside/Nucleotide Reverse Transcriptase Inhibitor (2-NRTI)-Containing Regimen
- First Posted Date
- 2014-11-06
- Last Posted Date
- 2025-01-09
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 41
- Registration Number
- NCT02285114
- Locations
- 🇺🇸
University of California Los Angeles, Los Angeles, California, United States
🇺🇸Children's Hospital Colorado, Aurora, Colorado, United States
🇺🇸St. Christopher's Hospital for Children, Philadelphia, Pennsylvania, United States
Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in HIV-1 Infected Adolescents
- First Posted Date
- 2014-10-28
- Last Posted Date
- 2018-11-19
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 60
- Registration Number
- NCT02276612
Study to Evaluate Safety, Pharmacokinetics, and Antiviral Activity of Bictegravir (GS-9883) in Human Immunodeficiency Virus (HIV)-1 Infected Participants
- First Posted Date
- 2014-10-27
- Last Posted Date
- 2020-11-09
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 23
- Registration Number
- NCT02275065
Long Term Follow-up Registry of Individuals Treated in A Gilead-Sponsored Trial in Individuals With Chronic Hepatitis B Infection
- Conditions
- Chronic Hepatitis B
- First Posted Date
- 2014-10-07
- Last Posted Date
- 2017-10-03
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 241
- Registration Number
- NCT02258581
- Locations
- 🇮🇹
IRCCS Ospedale Casa Sollievo della Sofferenza, San Giovanni Rotondo, Foggia, Italy
🇨🇦Liver and Intestinal Research Centre, Vancouver, British Columbia, Canada
🇰🇷Samsung Medical Center, Seoul, Korea, Republic of